ARDX
Ardelyx Inc
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 480.47M; Volume: 77.74K; AvgVol 3m: 547.26K; Beta: 1.86;
Cost estimate:
P/E: –; EPS: -1.19; EPS growth quarter/prev quarter: 31.10%;
EPS growth this year: 9.30%; EPS growth past 5 years: -53.50%;
EPS ttm: -1.19;
P/S: 61.75; P/B: 3.39; P/Cashflow: 2.50; P/FCF: ;
Sales: 8.31M; Sales growth quarter/prev quarter: 10100.00%; Sales growth past 5 years: -30.10%;
Profitability:
Gross Margin: 91.10%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -43.60%; ROE – return on equity: -65.90%; LT Debt/Equity: 0.25; Total Debt/Equity: 0.34;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 10.10%; Insider Transactions:-4.45%;
Institutional Ownership: 87.40%; Institutional Transactions: 1.33%;
Data update: 07/10/2020.